Navigation Links
Hospira Expands Board of Directors With Election of Dennis M. Fenton

LAKE FOREST, Ill., July 31, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that Dennis M. Fenton, Ph.D., has been elected to the company's board of directors. Dr. Fenton, a recognized manufacturing and biologics expert, has more than 30 years of healthcare industry experience. The addition of Dr. Fenton expands Hospira's board to 11 directors, 10 of whom are independent. 

"We are excited to welcome Dennis to Hospira's board of directors," said John C. Staley, chairman of the board. "His impressive track record of results-oriented leadership and pioneering contributions to biological manufacturing and operations quality make him an excellent fit."

F. Michael Ball, chief executive officer, added, "Dennis brings unparalleled experience in the pharmaceutical and biotechnology space, with differentiated expertise that spans manufacturing and quality overall, and biologics in particular. His appointment supports Hospira's commitment to establish manufacturing as a competitive advantage."

Dr. Fenton, 60, spent more than two decades at Amgen, where he served as one of the company's longest-tenured employees and its executive vice president of Operations until his retirement in 2008. Prior to Amgen, Dr. Fenton served as a senior research scientist at Pfizer.

Dr. Fenton is a member of the Society for Industrial Microbiology, held previous memberships in the American Chemical Society, the American Society for Microbiology and the Parenteral Drug Association, and was a director of the Biotechnology Industry Organization (BIO) and National Health Foundation. He currently serves on the boards of Dendreon Corporation, Napo Pharmaceuticals, Genelux Corporation, Xenoport and Kythera Biopharmaceuticals; and is a trustee of the Keck Graduate Institute and Rutgers University. A native of New York, Dr. Fenton holds a Bachelor of Science degree in biology from Manhattan College and a doctorate in microbiology from Rutgers University.

About Hospira
Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Reports First-Quarter 2012 Results
3. Hospira to Present at Upcoming Investor Conferences
4. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
5. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
6. Hospira to Host Conference Call for Second-quarter 2012 Results
7. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
8. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
9. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
10. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
11. S1 Biopharma Expands Focus to Include Male Sexual Health
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):